Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.
Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res. 2014 Jul; 2(7):598-605.